Quotient Sciences have made a number of submissions through the HRA/MHRA Combined Ways of Working Pilot
The HRA and MHRA have been exploring opportunities to improve the service being offered for the approval and ongoing management of Clinical Trials of Medicinal Products (CTIMPs) and launched a pilot to test an integrated process – the Combined Ways of Working Pilot.
Quotient Sciences Significantly Expands Formulation and Manufacturing in UK
Quotient Sciences, a leading drug development services organization, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading, U.K., facility. The program’s investment has tripled the site’s GMP capacity, added new equipment for solid oral dose manufacturing and significantly increased staffing levels.
Arcinova, a Quotient Sciences business, increases GC-MS/MS capabilities with new system
Arcinova, a Quotient Sciences business, increase GC-MS/MS capabilities with purchase of new Thermo Scientific TSQ Duo triple quadrupole.
Quotient Sciences Launches as the New Global Identity for Quotient Clinical
Quotient Clinical, the drug development services organization, announces its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma and SeaView Research. This new identity signifies a global footprint and an extended range of services, and symbolizes the commitment to ensuring a consistent and high-quality experience for customers.
Quotient Sciences signs agreement with Nuformix to evaluate cocrystal formulations using Translational Pharmaceutics®
Quotient Sciences has signed an agreement with Nuformix Technologies Limited to evaluate the clinical performance of Nuformix’ lead pharmaceutical cocrystal, NXP001, which is based on a currently marketed treatment in the field of oncology supportive care.